Targeting Bruton's Tyrosine Kinase in CLL von Ahn, Inhye E., Brown, Jennifer R.

Volltext

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia von Ahn, Inhye E., Underbayev, Chingiz, Albitar, Adam, Herman, Sarah E.M., Tian, Xin, Maric, Irina, Arthur, Diane C., Wake, Laura, Pittaluga, Stefania, Yuan, Constance M., Stetler-Stevenson, Maryalice, Soto, Susan, Valdez, Janet, Nierman, Pia, Lotter, Jennifer, Xi, Liqiang, Raffeld, Mark, Farooqui, Mohammed, Albitar, Maher, Wiestner, Adrian

Volltext

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study von Ahn, Inhye E., Farooqui, Mohammed Z.H., Tian, Xin, Valdez, Janet, Sun, Clare, Soto, Susan, Lotter, Jennifer, Housel, Stephanie, Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Calvo, Katherine R., Nierman, Pia, Hughes, Thomas E., Saba, Nakhle S., Marti, Gerald E., Pittaluga, Stefania, Herman, Sarah E.M., Niemann, Carsten U., Pedersen, Lone B., Geisler, Christian H., Childs, Richard, Aue, Georg, Wiestner, Adrian

Volltext

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era von Robinson, Hannah R., Qi, Junpeng, Cook, Erika M., Nichols, Cydney, Dadashian, Eman L., Underbayev, Chingiz, Herman, Sarah E.M., Saba, Nakhle S., Keyvanfar, Keyvan, Sun, Clare, Ahn, Inhye E., Baskar, Sivasubramanian, Rader, Christoph, Wiestner, Adrian

Volltext

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations von Ahn, Inhye E, Tian, Xin, Wiestner, Adrian

Volltext

Cardiovascular adverse events of ibrutinib von Ahn, Inhye E.

Volltext

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib von Vitale, Candida, Ahn, Inhye E, Sivina, Mariela, Ferrajoli, Alessandra, Wierda, William G, Estrov, Zeev, Konoplev, Sergej N, Jain, Nitin, O'Brien, Susan, Farooqui, Mohammed, Keating, Michael J, Wiestner, Adrian, Burger, Jan A

Volltext

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib von Ahn, Inhye E., Jerussi, Theresa, Farooqui, Mohammed, Tian, Xin, Wiestner, Adrian, Gea-Banacloche, Juan

Volltext

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines von Pleyer, Christopher, Ali, Mir A., Cohen, Jeffrey I., Tian, Xin, Soto, Susan, Ahn, Inhye E., Gaglione, Erika M., Nierman, Pia, Marti, Gerald E., Hesdorffer, Charles, Lotter, Jennifer, Superata, Jeanine, Wiestner, Adrian, Sun, Clare

Volltext

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL von Ahn, Inhye E., Basumallik, Neil, Tian, Xin, Soto, Susan, Wiestner, Adrian

Volltext

Therapeutic targeting of apoptosis in chronic lymphocytic leukemia von Ahn, Inhye E., Davids, Matthew S.

Volltext

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials von Allan, John N., Shanafelt, Tait, Wiestner, Adrian, Moreno, Carol, O’Brien, Susan M., Li, Jianling, Krigsfeld, Gabriel, Dean, James P., Ahn, Inhye E.

Volltext

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model von Ahn, Inhye E., Tian, Xin, Ipe, David, Cheng, Mei, Albitar, Maher, Tsao, L. Claire, Zhang, Lei, Ma, Wanlong, Herman, Sarah E. M., Gaglione, Erika M., Soto, Susan, Dean, James P., Wiestner, Adrian

Volltext

Selecting initial therapy in CLL von Ahn, Inhye E, Brown, Jennifer R

Volltext

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib von Sun, Clare, Nierman, Pia, Kendall, Ellen K., Cheung, Jean, Gulrajani, Michael, Herman, Sarah E.M., Pleyer, Christopher, Ahn, Inhye E., Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Gaglione, Erika M., Harris, Hailey M., Pittaluga, Stefania, Wang, Min Hui, Patel, Priti, Farooqui, Mohammed Z.H., Izumi, Raquel, Hamdy, Ahmed, Covey, Todd, Wiestner, Adrian

Volltext

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib von Brieghel, Christian, Aarup, Kathrine, Torp, Mathias H., Andersen, Michael A., Yde, Christina W., Tian, Xin, Wiestner, Adrian, Ahn, Inhye E., Niemann, Carsten U.

Volltext

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL von Mhibik, Maissa, Gaglione, Erika M., Eik, David, Kendall, Ellen K., Blackburn, Amy, Keyvanfar, Keyvan, Baptista, Maria Joao, Ahn, Inhye E., Sun, Clare, Qi, Junpeng, Rader, Christoph, Wiestner, Adrian

Volltext

Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib von Baptista, Maria Joao, Baskar, Sivasubramanian, Gaglione, Erika M., Keyvanfar, Keyvan, Ahn, Inhye E., Wiestner, Adrian, Sun, Clare

Volltext

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma von Merryman, Reid W., Michaud, Laure, Redd, Robert, Mondello, Patrizia, Park, Hyesun, Spilberg, Gabriela, Robertson, Matthew, Taranto, Eleanor, Ahmed, Gulrayz, Chase, Matthew, Jeter, Erin, Ahn, Inhye E., Brown, Jennifer R., Crombie, Jennifer, Davids, Matthew S., Fisher, David C., Jacobsen, Eric, Jacobson, Caron A., Kim, Austin I., LaCasce, Ann S., Ng, Samuel Y., Odejide, Oreofe O., Parry, Erin M., Salles, Gilles, Zelenetz, Andrew D., Armand, Philippe, Schöder, Heiko, Jacene, Heather

Volltext

CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy von Alsadhan, Anfal, Chen, Jonathan, Gaglione, Erika M, Underbayev, Chingiz, Tuma, Pamela L, Tian, Xin, Freeman, Lita A, Baskar, Sivasubramanian, Nierman, Pia, Soto, Susan, Itsara, Andy, Ahn, Inhye E, Sun, Clare, Bibikova, Elena, Hartmann, Tanja Nicole, Mhibik, Maissa, Wiestner, Adrian

Volltext